Ocugen, Inc., a biotechnology leader in gene therapies for blindness diseases, announced on June 16, 2025, that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug $(IND.AU)$ amendment, allowing the initiation of a Phase 2/3 pivotal confirmatory trial for their modifier gene therapy candidate, OCU410ST. This therapy is being developed to treat Stargardt disease and other ABCA4-associated retinopathies. The FDA previously granted OCU410ST both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation, highlighting the urgent need for treatment options for these conditions. This regulatory approval marks a significant step forward in Ocugen's efforts to provide innovative treatments for patients affected by these debilitating diseases.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。